Molecule.one raised $4.6 million in a round led by Atmos Ventures.

Molecule.one, a Warsawa, Poland-based software developers of novel chemical synthesis solutions for synthetic chemists, announced the completion of a $4.6 million capital funding round.

The money was raised from a range of investors led by Atmos Ventures and joined by AME Cloud Ventures, Cherubic Ventures, Firlej Kastory, Inventures and Luminous Ventures.

Pre-seed investor Sunfish Partners also participated, along with a few notable individual investors, including Sebastian Guth, President of Bayer Pharmaceuticals for the Americas region.

Proceeds will be used as the company aims to expand the business in Europe and the United States.

Molecule.one, founded in 2016 by CEO Piotr Byrski and Paweł Włodarczyk-Pruszyński, developed a machine learning based software tool to be used for synthesis planning – the task of predicting how to physically make a given molecule, as a way of producing new drugs and treatments. The platform is based on AI models that achieve state-of-the-art results on publicly available and industry-recognized benchmarks.

The company is particularly focused on applying the technology in partnership with pharmaceutical & biotech companies that work to discover new small molecule drugs.

The market for small molecule drug discovery is projected to reach $50 billion by 2025.

Molecule.one previously raised $250k from Sunfish in 2019.